Tomer Babu

Tomer Babu

Auto-generated profile, based on publicly available information

Tomer Babu

Department of Chemistry The University of Texas at Austin 105 East 24th Street Austin Texas 78712‐1224 USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
TYThirumal Yempala
Thirumal Yempala
TBTomer Babu
Tomer Babu
SKSubhendu Karmakar
Subhendu Karmakar
ANAlina Nemirovski
Alina Nemirovski
MIMaisaloon Ishan
Maisaloon Ishan
DGDan Gibson
Dan Gibson

24 March 2020 in Inorganic Chemistry
Verified
Journal Article
Closed access
TBTomer Babu
Tomer Babu
ASAmrita Sarkar
Amrita Sarkar
SKSubhendu Karmakar
Subhendu Karmakar
CSClaudia Schmidt
Claudia Schmidt
DGDan Gibson
Dan Gibson

12 September 2023 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
ASAmrita Sarkar
Amrita Sarkar
VNVojtech Novohradsky
Vojtech Novohradsky
MMMoumita Maji
Moumita Maji
TBTomer Babu
Tomer Babu
LMLenka Markova
Lenka Markova
DGDan Gibson
Dan Gibson
A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co‐administration. The viability of CT26 cells co‐cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non‐treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co‐administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.

31 January 2023 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
TBTomer Babu
Tomer Babu
HGHiba Ghareeb
Hiba Ghareeb
UBUttara Basu
Uttara Basu
HSHemma Schueffl
Hemma Schueffl
STSarah Theiner
Sarah Theiner
DGDan Gibson
Dan Gibson
AuI‐carbene and PtIV−AuI‐carbene prodrugs display low to sub‐μM activity against several cancer cell lines and overcome cisplatin (cisPt) resistance. Linking a cisPt‐derived PtIV(phenylbutyrate) complex to a AuI‐phenylimidazolylidene complex2, yielded the most potent prodrug. While in vivo tests against Lewis Lung Carcinoma showed that the prodrug PtIV(phenylbutyrate)‐AuI‐carbene (7) and the 1 : 1 : 1 co‐administration of cisPt: phenylbutyrate:2efficiently inhibited tumor growth (≈95 %), much better than2(75 %) or cisPt (84 %),7exhibited only 5 % body weight loss compared to 14 % for2, 20 % for cisPt and >30 % for the co‐administration.7was much more efficient than2at inhibiting TrxR activity in the isolated enzyme, in cells and in the tumor, even though it was much less efficient than2at binding to selenocysteine peptides modeling the active site of TrxR. Organ distribution and laser‐ablation (LA)‐ICP‐TOFMS imaging suggest that7arrives intact at the tumor and is activated there.

8 January 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
TBTomer Babu
Tomer Babu
RMRam Pravin Kumar Muthuramalingam
Ram Pravin Kumar Muthuramalingam
WCWei Heng Chng
Wei Heng Chng
JYJia Ning Nicolette Yau
Jia Ning Nicolette Yau
SASourav Acharya
Sourav Acharya
DGDan Gibson
Dan Gibson
Cisplatin and oxaliplatin are Pt(II) anticancer agents that are used to treat several cancers, usually in combination with other drugs. Their efficacy is diminished by dose-limiting peripheral neuropathy (PN) that affects ∼70% of patients. PN is caused by selective accumulation of the platinum drugs in the dorsal root ganglia (DRG), which overexpress transporters for cisplatin and oxaliplatin. To date, no drug is recommended for the prevention of PN. We report that Pt(IV) prodrugs of cisplatin or oxaliplatin do not induce neuropathic pain in mice, likely due to the lower accumulation of platinum in the DRG compared with Pt(II) drugs. Moreover, the multitargeting prodrug that combines cisplatin with paclitaxel, both strong inducers of PN, efficiently inhibited tumor growth in vivo without inducing neuropathic pain. The high antitumor efficacy of Pt(IV) prodrugs and their micellar counterparts and the low level of neuropathic pain associated with them make them ideal candidates for clinical use in cancer therapy.

6 December 2023 in Inorganic Chemistry Frontiers
Verified
Journal Article
Open access
PDF file
AKAlexander Kastner
Alexander Kastner
TMTheresa Mendrina
Theresa Mendrina
TBTomer Babu
Tomer Babu
SKSubhendu Karmakar
Subhendu Karmakar
IPIsabella Poetsch
Isabella Poetsch
CKChristian Kowol
Christian Kowol
An albumin-binding cisplatin( iv )-gemcitabine complex was step-by-step improved based on stability, reduction, albumin-binding and in vivo data yielding a carboplatin( iv ) complex with distinctly improved overall survival and anticancer activity.